摘要
目的探讨奥曲肽治疗肝硬化合并上消化道出血的临床疗效。方法将医院2014年6月至2016年6月收治的90例肝硬化合并上消化道出血患者随机分为对照组和观察组,各45例。在常规治疗基础上,对照组患者给予垂体后叶素,观察组患者给予奥曲肽。结果观察组总有效率为91.11%,明显高于对照组的75.56%(χ~2=3.92,P<0.05);两组Child-Pugh评分、白蛋白、血红蛋白、凝血酶原时间(PT)比较,差异均有统计学意义(t=4.19,2.16,3.14,7.69,P<0.05);观察组平均止血时间为(22.4±12.8)h,明显短于对照组的(35.9±15.4)h(t=4.52,P<0.05);观察组不良反应发生率为8.89%,明显低于对照组的26.67%(χ~2=4.86,P<0.05)。结论奥曲肽治疗肝硬化合并上消化道出血疗效确切,安全性高,值得临床推广。
Objective To investigate the clinical effect of octreotide in the treatment of liver cirrhosis complicated with upper gastrointestinal hemorrhage（ UGIH）. Methods Totally 90 patients with liver cirrhosis complicated with UGIH in our hospital from June 2014 to June 2016 were randomly divided into the control group and the observation group,45 cases in each group. The control group was given pituitrin,while the observation group was given octreotide. Results The total effective rate of the observation group was 91. 11%,which was significantly higher than 75. 56% of the control group（ χ2 = 3. 92,P 0. 05）. The Child-Pugh score,albumin,hemoglobin,prothrombin time（ PT） between the two groups were statistically significant difference（ t = 4. 19,2. 16,3. 14,7. 69,P〈0. 05）. The average hemostasis time of the observation group was（ 22. 4 ± 12. 8） h,which were significantly shorter than（ 35. 9 ± 15. 4） h in the control group（ t = 4. 52,P〈0. 05）. The incidence rate of adverse reactions in the observation group was 8. 89%,which was significantly lower than26. 67% in the control group（ χ2 = 4. 86,P〈0. 05）. Conclusion Octreotide in the treatment of liver cirrhosis combined with UGIH has good effect and safety,it is worthy of clinical promotion.
出处
《中国药业》
CAS
2017年第16期57-59,共3页
China Pharmaceuticals
关键词
奥曲肽
垂体后叶素
肝硬化
上消化道出血
临床疗效
octreotide
pituitrin
hepatocirrhosis
upper gastrointestinal hemorrhage
clinical effect
